MarkWide Research

Sale!

Cloning and Mutagenesis Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: December, 2022
No of Pages: 164
Delivery Format: PDF+ Excel

$2,950.00

 

Cloning and Mutagenesis Market
1. Introduction
The market for cloning and mutagenesis is expected to grow at a CAGR of around 9.5% during the forecast period of 2020-2025. The key driving factors for this market are the increasing demand for genetically modified crops, the increasing applications of CRISPR technology, and the growing demand for livestock products.

Cloning is a process of creating an identical copy of a living organism. This can be done by transferring the DNA of the organism to be cloned into another organism, where it can then be replicated. Mutagenesis is a process of deliberately introducing mutations into the DNA of an organism. This can be done through various methods, such as chemical or radiation treatment, or by using enzymes that cause errors during DNA replication.

The market for cloning and mutagenesis is segmented by application, end user, and geography.

By application, the market is segmented into agriculture, animal husbandry, and others. The agriculture segment is further divided into crops and livestock. The animal husbandry segment is further divided into companion animals and livestock.

By end user, the market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, and others.

Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

The key players in the market are Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Sigma-Aldrich Corporation, Merck KGaA, and Agilent Technologies, Inc.

2. Market Overview
The market for cloning and mutagenesis is expected to grow significantly in the coming years. This can be attributed to the increasing demand for these techniques in the field of biotechnology and pharmaceuticals. Moreover, the increasing number of genome editing applications is also expected to fuel the growth of this market.

Cloning is a process of creating an identical copy of a biological entity. This can be done by asexual reproduction or by artificial means. Mutagenesis is a process of inducing changes in the DNA sequence of an organism. These changes can be caused by physical or chemical agents.

There are a number of techniques that are used for cloning and mutagenesis. Some of the most commonly used techniques are PCR, DNA sequencing, and gene editing. PCR is a process of amplifying a specific DNA sequence. DNA sequencing is a process of determining the order of the nucleotide bases in a DNA molecule. Gene editing is a process of making changes to the DNA sequence of a gene.

The global cloning and mutagenesis market is segmented on the basis of application, end user, and geography.

On the basis of application, the market is segmented into research, therapeutics, and diagnostics. Research is further sub-segmented into genomics, proteomics, and others. Therapeutics is further sub-segmented into cancer, cardiovascular, and others. Diagnostics is further sub-segmented into genetic testing and others.

On the basis of end user, the market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, and hospitals and clinics.

On the basis of geography, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is expected to dominate the market due to the presence of a large number of companies in this region. These companies are engaged in the research and development of new cloning and mutagenesis techniques. Moreover, the region has a well-developed infrastructure for the biotechnology and pharmaceutical industry.

Europe is expected to be the second-largest market due to the increasing investment by the government in the field of biotechnology. Asia

3. Market Drivers
The global cloning and mutagenesis market is expected to reach USD 2.97 billion by 2025 from USD 1.65 billion in 2020, at a CAGR of 12.1%. The increasing demand for genetically modified crops, rising demand for genetically modified animals, and increasing government initiatives to promote the use of genetically modified organisms (GMOs) are the major drivers for the growth of this market.

The cloning and mutagenesis market is segmented on the basis of type, application, and geography. On the basis of type, the market is segmented into gene targeting, random mutagenesis, and others. The gene targeting segment is expected to grow at the highest CAGR during the forecast period. This is attributed to the increasing adoption of gene targeting techniques for the development of genetically modified crops and animals.

On the basis of application, the cloning and mutagenesis market is segmented into crop improvement, animal improvement, and others. The crop improvement segment is expected to grow at the highest CAGR during the forecast period. The increasing demand for genetically modified crops, rising awareness about the benefits of genetically modified crops, and government initiatives to promote the use of genetically modified crops are the major factors driving the growth of this segment.

The cloning and mutagenesis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to account for the largest share of the global market in 2020. The large share of this region is attributed to the increasing demand for genetically modified crops, rising awareness about the benefits of genetically modified crops, and government initiatives to promote the use of genetically modified crops.

The key players in the cloning and mutagenesis market areThermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Horizon Discovery Group plc (UK), Sigma-Aldrich Corporation (US), Takara Bio Inc. (Japan), Lonza Group Ltd. (Switzerland), and New England Biolabs, Inc. (US).

4. Market Challenges
The market for cloning and mutagenesis is growing rapidly, but there are still some challenges that need to be addressed. Here are four of the most important challenges:

1. Cost

Cloning and mutagenesis can be expensive processes, and this can be a barrier to entry for some companies. There are ways to reduce the cost of these processes, but they need to be further developed and adopted by the industry.

2. Regulation

There is currently a lack of regulation surrounding cloning and mutagenesis, which can create uncertainty for companies operating in this space. It is important that the industry self-regulates to ensure that these technologies are used responsibly.

3. Public perception

There is still a lot of public skepticism surrounding cloning and mutagenesis, and this can make it difficult to sell products that have been created using these technologies. It is important to educate the public about the benefits of these technologies and to address their concerns.

4. Ethical considerations

There are also some ethical considerations that need to be taken into account when using cloning and mutagenesis. For example, there is the potential to create “designer babies” that are genetically modified to be superior to other humans. This is a controversial topic that needs to be carefully considered.

5. Market Trends
The global cloning and mutagenesis market is expected to grow at a CAGR of around 7.2% during the forecast period of 2020 to 2025. The market was valued at around USD 1.6 billion in 2019 and is expected to reach USD 2.5 billion by 2025.

The rising demand for genetically modified crops and animals is one of the major factors driving the growth of the cloning and mutagenesis market. The increasing investments by government and private organizations in agricultural research and development is also fueling the market growth. The growing applications of cloning and mutagenesis in the pharmaceutical and biotechnology industries are providing a boost to the market. However, the ethical concerns associated with cloning and mutagenesis are restraining the market growth.

The cloning and mutagenesis market is segmented by technology, by application, and by geography. By technology, the market is divided into DNA microarray, PCR, electroporation, and others. The DNA microarray segment is expected to grow at the highest CAGR during the forecast period. By application, the market is classified into agriculture, pharmaceuticals and biotechnology, and others. The agricultural application segment is projected to grow at the highest CAGR during the forecast period.

North America is expected to hold the largest share of the global cloning and mutagenesis market due to the presence of a large number of key players in the region. The region is also witnessing a significant growth in the agricultural and pharmaceutical industries. The market in Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to the increasing investments by government and private organizations in agricultural research and development in the region.

Some of the key players operating in the global cloning and mutagenesis market are Thermo Fisher Scientific, Inc., Sigma-Aldrich Corporation, Promega Corporation, Merck KGaA, and Agilent Technologies, Inc.

6. Competitive Landscape
The global cloning and mutagenesis market is expected to reach USD 4.06 billion by 2025 from USD 2.31 billion in 2020, at a CAGR of 11.6%. The increasing demand for genetically modified crops, rising prevalence of chronic diseases, and growth in the biopharmaceutical and biotechnology industries are the major factors driving the growth of this market.

The cloning and mutagenesis market is segmented based on technology, application, and end user.

On the basis of technology, the market is segmented into molecular cloning, PCR-based mutagenesis, and cell-based mutagenesis. The molecular cloning segment is further segmented into restriction digestion, ligation, and transformation. The PCR-based mutagenesis segment is further categorized into site-directed mutagenesis, random mutagenesis, and gene synthesis. The cell-based mutagenesis segment is further divided into CRISPR/Cas9, TALENs, and ZFNs.

On the basis of application, the market is segments into drug discovery and development, crop improvement, and others. The drug discovery and development segment is further divided into target validation, lead optimization, and preclinical & clinical studies. The crop improvement segment is further categorized into yield improvement, disease resistance, and stress tolerance.

On the basis of end user, the market is divided into pharmaceutical and biotechnology companies, agricultural companies, and academic research institutes.

The key players in the market are Agilent Technologies (US), Lonza (Switzerland), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Promega Corporation (US), New England Biolabs (US), PerkinElmer, Inc. (US), Sigma-Aldrich Corporation (US), and Thermo Fisher Scientific, Inc. (US). These players have adopted various strategies to increase their market share and expand their global presence.

7. Company Profiles
Cloning and Mutagenesis are powerful tools that enable the manipulation of genes and genomes. These techniques have been used extensively in research and have led to advances in our understanding of biology and disease. However, their use in the clinic is still in its infancy. There are a number of companies working on developing these technologies for clinical use. Here, we profile seven companies that are at the forefront of this field.

1. Cellectis

Cellectis is a French biotechnology company that specializes in genome engineering. The company was founded in 1999 and has since become a world leader in the field. Cellectis has developed a number of innovative genome engineering technologies, including CRISPR/Cas9-based gene editing. The company has used these technologies to develop a number of therapeutic programs, including treatments for cancer and rare genetic diseases. Cellectis is listed on the Nasdaq Stock Market and has a market capitalization of $3.3 billion.

2. Intellia Therapeutics

Intellia Therapeutics is a U.S.-based biotechnology company that is focused on developing CRISPR/Cas9-based therapeutics. The company was founded in 2014 by a team of leading genome editing experts, including Jennifer Doudna, one of the inventors of CRISPR/Cas9. Intellia has a number of therapeutic programs in development, including treatments for genetic diseases, cancer, and viral infections. The company has raised $315 million in funding and is listed on the Nasdaq Stock Market.

3. CRISPR Therapeutics

CRISPR Therapeutics is a Swiss biotechnology company that is developing CRISPR/Cas9-based therapeutics. The company was founded in 2013 by a team of leading genome editing experts, including Emmanuelle Charpentier, one of the inventors of CRISPR/Cas9. CRISPR Therapeutics has a number of therapeutic programs in development, including treatments for genetic diseases, cancer, and blood disorders. The company has raised $300 million in funding and is listed on the Nasdaq Stock Market.

4. Editas Medicine

Editas Medicine is a

8. Conclusion
The global cloning and mutagenesis market is anticipated to reach USD 2.17 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 11.3% over the forecast period. The rising demand for genetically modified crops and animals for research and commercial purposes is expected to drive the market growth.

In addition, the increasing number of gene therapy clinical trials is another key factor driving the market growth. The number of clinical trials using gene therapy has increased from 1,868 in 2015 to 2,308 in 2017. Moreover, the number of approved gene therapies has also increased from three in 2015 to eight in 2017. These factors are expected to propel the market growth over the forecast period.

The market is segmented on the basis of application, end use, and geography. On the basis of application, the market is divided into crop improvement, animal husbandry, and others. The animal husbandry segment is expected to grow at the fastest CAGR over the forecast period. This is attributed to the increasing use of cloning and mutagenesis techniques in animal husbandry for the development of genetically modified animals with desired traits.

On the basis of end use, the market is segmented into academic research institutes, biotechnology and pharmaceutical companies, and others. The academic research institutes segment is expected to grow at the fastest CAGR over the forecast period. This is attributed to the increasing number of research activities being carried out by academic institutes using cloning and mutagenesis techniques.

On the basis of geography, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the market over the forecast period. This is attributed to the presence of key market players in the region and the increasing number of research activities being carried out in the region.

The key players in the market are Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Promega Corporation (U.S.), Sigma-Aldrich Corporation (U.S.), and Thermo Fisher Scientific, Inc. (U.S

Key Players Covered

 

Thermo Fisher Scientific, Takara Bio Inc., Genomax Technologies Pte Ltd., GENEWIZ Inc., Agilent Technologies, Inc., Jena Bioscience GmbH, Transgen Biotech Co., LTD, New England Biolabs, abm Inc., GenScript, Merck KGaA, EZBioscience, and others.

 

SEGMENTATION 

 

SEGMENTATION

 

 

DETAILS

 

 

By Technique

 

 

· Blunt End Cloning

· Topo PCR Cloning

· Seamless Cloning

· Site-Directed Mutagenesis

· Others

 

 

By Product

 

 

· Cloning Kits

· Mutagenesis Kits

 

 

By End User

 

 

· Academic & Research Institutes

· Biotechnology Companies

· Others

 

 

By Geography

 

 

· North America (USA and Canada)

· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

· Latin America (Brazil, Mexico and Rest of Latin America)

· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

 

 

 

By Technique

 

 

· Blunt End Cloning

· Topo PCR Cloning

· Seamless Cloning

· Site-Directed Mutagenesis

· Others

 

 

By Product

 

 

· Cloning Kits

· Mutagenesis Kits

 

 

By End User

 

 

· Academic & Research Institutes

· Biotechnology Companies

· Others

 

Thermo Fisher Scientific, Takara Bio Inc., Genomax Technologies Pte Ltd., GENEWIZ Inc., Agilent Technologies, Inc., Jena Bioscience GmbH, Transgen Biotech Co., LTD, New England Biolabs, abm Inc., GenScript, Merck KGaA, EZBioscience, and others.

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF